(January 8, 2019, 8:43 AM EST) -- WASHINGTON, D.C. — The U.S. Supreme Court on Jan. 7 questioned whether the term “stress fracture” can include atypical fractures of the femur and whether warning about a fracture risk from the osteoporosis drug Fosamax could lead to “over-warning” and doctors refusing to prescribe the drug to post-menopausal women (Merck Sharp & Dohme Corp. v. Doris Albrecht, et al., No. 17-290, U.S. Sup.)....